Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2018-09-14
- Employees
- -
- Market Cap
- -
- Website
- http://en.novatim-zj.com/
A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors.
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
- Target Recruit Count
- 212
- Registration Number
- NCT06928363
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome
Phase 1
Not yet recruiting
- Conditions
- POEMS Syndrome
- Interventions
- Biological: KQ-2003 CAR T-cells
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT06518876
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Biological: KQ-2003 CAR T-cells
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT06223646
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China
Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
- Target Recruit Count
- 189
- Registration Number
- NCT06175780
- Locations
- 🇨🇳
The Fifth Medical Center of the Chinese PLA General Hospital, Beijing, Beijing, China
🇨🇳Tianjin Cancer Hospital, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital Bengbu Medical College, Bengbu, Anhui, China
© Copyright 2025. All Rights Reserved by MedPath